“In essence, big pharma often uses a "crawl, walk, run" approach, starting with a focused indication to de-risk development and then expanding to larger, more competitive markets as the drug proves its value” “it's common for large pharmaceutical companies (big pharma) to initially target specific, often smaller, cancer indications (like rare cancers or specific subtypes) as they become successful with a drug. This approach allows them to build a foundation of evidence for the drug's efficacy and safety in a more manageable setting, before expanding to broader, more competitive indications”
IMM Price at posting:
26.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)